Stephenson National Bank & Trust trimmed its position in shares of ICON Public Limited (NASDAQ:ICLR) by 7.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 847 shares of the medical research company’s stock after selling 65 shares during the quarter. Stephenson National Bank & Trust’s holdings in ICON Public were worth $162,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. Nelson Van Denburg & Campbell Wealth Management Group LLC boosted its stake in shares of ICON Public by 54.2% during the second quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,020 shares of the medical research company’s stock valued at $340,000 after purchasing an additional 710 shares in the last quarter. JLB & Associates Inc. raised its position in shares of ICON Public by 5.6% during the second quarter. JLB & Associates Inc. now owns 28,275 shares of the medical research company’s stock worth $4,763,000 after acquiring an additional 1,504 shares during the last quarter. Handelsbanken Fonder AB bought a new position in shares of ICON Public during the second quarter worth about $2,123,000. Sigma Planning Corp bought a new position in shares of ICON Public during the second quarter worth about $273,000. Finally, Vident Investment Advisory LLC bought a new position in shares of ICON Public during the second quarter worth about $424,000. 83.74% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research upgraded ICON Public from a “hold” rating to a “buy” rating and set a $218.00 price objective for the company in a research report on Tuesday. Deutsche Bank Aktiengesellschaft raised their price objective on ICON Public from $170.00 to $179.00 and gave the stock a “hold” rating in a research report on Friday, October 23rd. UBS Group raised their price objective on ICON Public from $188.00 to $194.00 and gave the stock a “neutral” rating in a research report on Monday, July 27th. Mizuho lifted their target price on ICON Public from $195.00 to $217.00 and gave the stock a “buy” rating in a report on Friday, October 23rd. Finally, BidaskClub downgraded ICON Public from a “hold” rating to a “sell” rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $186.45.
ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, October 21st. The medical research company reported $1.72 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.55 by $0.17. ICON Public had a return on equity of 22.21% and a net margin of 12.03%. Research analysts predict that ICON Public Limited will post 6.26 earnings per share for the current fiscal year.
ICON Public Profile
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Further Reading: Trading Ex-Dividend
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICON Public Limited (NASDAQ:ICLR).
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.